Minerva Advisors Boosted By $2.31 Million Its Entercom Communications (ETM) Stake; Trillium Therapeutics Inchares (TRIL) Shorts Raised By 16.9%

June 23, 2018 - By Ellis Scott

Entercom Communications Corp. (NYSE:ETM) Logo

Minerva Advisors Llc increased Entercom Communications (ETM) stake by 96.71% reported in 2018Q1 SEC filing. Minerva Advisors Llc acquired 256,618 shares as Entercom Communications (ETM)’s stock declined 31.43%. The Minerva Advisors Llc holds 521,978 shares with $5.04 million value, up from 265,360 last quarter. Entercom Communications now has $1.11 billion valuation. The stock increased 1.29% or $0.1 during the last trading session, reaching $7.85. About 4.23M shares traded or 87.37% up from the average. Entercom Communications Corp. (NYSE:ETM) has declined 25.81% since June 23, 2017 and is downtrending. It has underperformed by 38.38% the S&P500. Some Historical ETM News: 08/05/2018 – Entercom 1Q Adj EPS 0c; 15/05/2018 – Aristeia Capital LLC Exits Position in Entercom Comms; 08/03/2018 – ENTERCOM COMMUNICATIONS CORP QTRLY ADJ SHR $0.16; 16/05/2018 – Entercom Comms Presenting at Gamco Conference Jun 7; 03/05/2018 – United States Traffic Network Signs New Agreement with Entercom Communications Corp; 08/03/2018 – Entercom 4Q EPS $2.62; 26/04/2018 – ENTERCOM COMMUNICATIONS CORP ETM.N -NBC 5 DALLAS-FORT WORTH, TELEMUNDO 39 AND ENTERCOM ANNOUNCE MULTI-YEAR MEDIA PARTNERSHIP; 16/03/2018 – E.W. Scripps activist campaign could add independent pressure on family –; 08/03/2018 – Entercom 4Q Net $232.4M; 14/03/2018 – Philly.com: Radio giant Entercom looking to move HQ from Bala Cynwyd to Philly waterfront

Trillium Therapeutics Inchares (NASDAQ:TRIL) had an increase of 16.9% in short interest. TRIL’s SI was 176,400 shares in June as released by FINRA. Its up 16.9% from 150,900 shares previously. With 64,500 avg volume, 3 days are for Trillium Therapeutics Inchares (NASDAQ:TRIL)’s short sellers to cover TRIL’s short positions. The SI to Trillium Therapeutics Inchares’s float is 2.43%. The stock decreased 1.48% or $0.1 during the last trading session, reaching $6.65. About 70,633 shares traded. Trillium Therapeutics Inc. (NASDAQ:TRIL) has risen 11.93% since June 23, 2017 and is uptrending. It has underperformed by 0.64% the S&P500. Some Historical TRIL News: 10/04/2018 – TRILLIUM THERAPEUTICS INC – SUCCESSFUL BROAD SIGNAL-SEEKING EFFORTS IDENTIFY T-CELL LYMPHOMA AS AN INDICATION RESPONSIVE TO TTI-621 THERAPY; 11/05/2018 – TRILLIUM THERAPEUTICS INC – QTRLY SHR $0.65; 26/03/2018 – Trillium Dental Announces New Brand Identity; 20/03/2018 – TRILLIUM THERAPEUTICS INC TRIL.TO – TRILLIUM THERAPEUTICS’ TTI-621 RECEIVES ORPHAN DRUG DESIGNATION FOR TREATMENT OF CUTANEOUS T-CELL LYMPHOMA; 13/03/2018 – Trillium Therapeutics Granted Orphan Drug Status by FDA; 14/03/2018 – Moody’s Assigns Definitive Ratings To Trillium Credit Card Trust Ii 2018-1 Abs; 12/04/2018 – Trillium Therapeutics to Report Preclinical Data on TTI-621 and TTI-622 at the AACR Annual Meeting 2018; 10/04/2018 – TRILLIUM THERAPEUTICS PROVIDES UPDATE ON ITS TTI-621 AND TTI-622 CLINICAL PROGRAMS; 06/03/2018 GUIDANCE: BANK OF NOVA SCOTIA $400M TRILLIUM CREDIT CARD ABS; 17/04/2018 – TRILLIUM ASSET MANAGEMENT URGES FACEBOOK SHAEHOLDERS TO VOTE IN FAVOR OF PROPOSAL REGARDING RISK OVERSIGHT COMMITTEE – SEC FILING

Among 4 analysts covering Trillium Therapeutics (NASDAQ:TRIL), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Trillium Therapeutics had 8 analyst reports since August 26, 2015 according to SRatingsIntel. Leerink Swann initiated Trillium Therapeutics Inc. (NASDAQ:TRIL) on Friday, April 13 with “Hold” rating. The stock of Trillium Therapeutics Inc. (NASDAQ:TRIL) has “Buy” rating given on Wednesday, July 5 by Cowen & Co. H.C. Wainwright maintained Trillium Therapeutics Inc. (NASDAQ:TRIL) on Monday, May 14 with “Buy” rating. The stock has “Buy” rating by Ladenburg on Thursday, June 8. The rating was maintained by H.C. Wainwright with “Buy” on Monday, March 12. The rating was upgraded by Zacks on Wednesday, August 26 to “Hold”. The stock of Trillium Therapeutics Inc. (NASDAQ:TRIL) has “Buy” rating given on Thursday, December 14 by H.C. Wainwright.

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company has market cap of $88.15 million. The companyÂ’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. It currently has negative earnings. The Company’s product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase.

More notable recent Trillium Therapeutics Inc. (NASDAQ:TRIL) news were published by: Globenewswire.com which released: “Trillium Therapeutics Completes Amendment to SIRPaFc License Agreement” on June 15, 2018, also Seekingalpha.com with their article: “Trillium up 13% premarket” published on June 21, 2018, Nasdaq.com published: “Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders” on June 05, 2018. More interesting news about Trillium Therapeutics Inc. (NASDAQ:TRIL) were released by: Nasdaq.com and their article: “Trillium Therapeutics Announces “At-The-Market” Issuance Program and Filing of Prospectus Supplement” published on June 19, 2018 as well as Seekingalpha.com‘s news article titled: “Early-stage study commences for Trillium’s blood cancer candidate TTI-622” with publication date: June 14, 2018.

Investors sentiment decreased to 0.77 in Q1 2018. Its down 7.18, from 7.95 in 2017Q4. It is negative, as 37 investors sold ETM shares while 55 reduced holdings. 20 funds opened positions while 51 raised stakes. 115.14 million shares or 48.20% less from 222.30 million shares in 2017Q4 were reported. Germany-based Deutsche National Bank & Trust Ag has invested 0.01% in Entercom Communications Corp. (NYSE:ETM). Alliancebernstein Lp has 0% invested in Entercom Communications Corp. (NYSE:ETM) for 155,511 shares. Private Advisor Grp Inc Limited Company stated it has 11,018 shares. State Of New Jersey Common Pension Fund D owns 446,038 shares for 0.02% of their portfolio. Phocas Financial accumulated 516,807 shares. Laurion Capital Mngmt Lp reported 19,200 shares stake. State Street reported 2.98 million shares stake. Kbc Grp Nv reported 476,712 shares. Wells Fargo & Co Mn owns 342,732 shares for 0% of their portfolio. Prudential stated it has 413,128 shares or 0.01% of all its holdings. Tower Ltd Liability (Trc) has 9,468 shares. Advisory Networks Ltd holds 220 shares or 0% of its portfolio. Rbf Limited invested in 10,000 shares or 0.01% of the stock. 577 were reported by First Personal Financial Services. Point72 Asia (Hong Kong) Limited reported 0.02% stake.

Among 3 analysts covering Entercom Communications (NYSE:ETM), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Entercom Communications had 6 analyst reports since August 18, 2015 according to SRatingsIntel. The stock of Entercom Communications Corp. (NYSE:ETM) earned “Buy” rating by Noble Financial on Monday, July 24. The company was maintained on Monday, July 31 by Noble Financial. Noble Financial maintained the shares of ETM in report on Monday, November 27 with “Buy” rating. Stephens initiated the shares of ETM in report on Friday, December 11 with “Equal-Weight” rating. The firm has “Outperform” rating given on Tuesday, August 18 by Wells Fargo.

Another recent and important Entercom Communications Corp. (NYSE:ETM) news was published by Seekingalpha.com which published an article titled: “Entercom Communications Is A Buy” on June 12, 2018.

Since March 9, 2018, it had 15 buys, and 1 insider sale for $34.70 million activity. Another trade for 150,000 shares valued at $1.13 million was bought by FIELD JOSEPH M. Levin Eugene D had sold 85,256 shares worth $658,745 on Monday, May 21. On Wednesday, May 16 the insider Philips Robert E bought $50,009.

Entercom Communications Corp. (NYSE:ETM) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Posts